HOME >> BIOLOGY >> NEWS
Soliris (eculizumab) data to be presented at American Society of Hematology

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) today announced that abstracts relating to Soliris (eculizumab) for patients with paroxysmal nocturnal hemoglobinuria (PNH) have been published by the American Society of Hematology (ASH). Each of these abstracts will be presented at the 2006 ASH Annual Meeting in Orlando, Florida, December 9th to 12th by leading investigators in the Soliris (eculizumab) PNH clinical studies. Copies of the abstracts are available and can be viewed on-line through the ASH website: www.hematology.org/meetings/abstracts.cfm. Access to the on-line abstracts may require registration, for which there is no charge.

The following abstracts will be presented in oral sessions:

  • "The Terminal Complement Inhibitor Eculizumab Reduces Thrombosis in Patients with Paroxysmal Nocturnal Hemoglobinuria"
    Dr. Peter Hillmen et al.
    Time: Sunday, December 10th at 5:00pm
    Room 315
  • "Treatment with the Terminal Complement Inhibitor Eculizumab Improves Anemia in Patients with Paroxysmal Nocturnal Hemoglobinuria: Phase III TRIUMPH Study Results"
    Dr. Jrg Schubert et al.
    Time: Sunday, December 10th at 5:15pm
    Room 315

The following abstracts will be presented in poster sessions:

  • "Safety and Efficacy of the Terminal Complement Inhibitor Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria: SHEPHERD Phase III Clinical Study"
    Poster # 99-I
    Dr. Neal S. Young et al.
    Time: Saturday, December 9th at 9:00am
    Hall E-1
  • "Blockade of Intravascular Hemolysis in PNH with the Terminal Complement Inhibitor Eculizumab Unmasks Low-Level Hemolysis Potentially Occurring through C3 Opsonization"
    Poster #100-I
    Dr. Anita Hill et
    '"/>


Contact: Tony Russo
tony.russo@eurorscg.com
212-845-4251
Euro RSCG Life NRP
8-Dec-2006


Page: 1 2

Related biology news :

1. Clinical trial data regarding NKTR-061 will be presented at ATS International Conference
2. Data presented at ISHLT meeting confirm RNA analysis can identify rejection in lung transplant recip
3. Latest plant health research to be presented in San Diego
4. Presidential Recognition Awards presented at the 2007 AIUM Annual Convention
5. Agronomy, crop, soils research presented in Indianapolis
6. UW-Madison work on stem cells, cardiac health to be presented at ACS
7. Weizmann Women & Science Award presented to Dr. Mary-Claire King
8. IOF-Novartis Young Scholars Awards presented to seven researchers from six countries
9. Coma misrepresented in movies
10. Latest plant disease research to be presented in Quebec City
11. AIUM Presidential Recognition Awards presented

Post Your Comments:
(Date:8/21/2014)... Carolina State University have developed a novel and versatile ... applications for creating new materials as well as for ... technique allows us to model much larger and more ... quickly," says Nan Li, lead author of a paper ... State,s Department of Materials Science and Engineering. "This is ...
(Date:8/20/2014)... 2014 George E. Fox, a John and Rebecca Moores ... (UH), was named a fellow in the International Society for ... Fox is one of four members two from the ... as fellows in 2014. Fellows are elected every three years, ... 500 members from more than 20 countries, the ISSOL includes ...
(Date:8/20/2014)... SALT LAKE CITY Researchers at Huntsman Cancer Institute (HCI) ... mutated forms of the gene that encodes BCR-ABL, the ... (CML). According to the American Cancer Society, nearly 6,000 ... , Drugs already in use, called tyrosine kinase inhibitors ... disease. They do not cure CML but control it ...
Breaking Biology News(10 mins):Researchers develop models to study polyelectrolytes, including DNA and RNA 2UH professor named fellow by International Astrobiology Society 2Blueprint for next generation of chronic myeloid leukemia treatment 2
(Date:8/21/2014)... Louis, MO (PRWEB) August 21, 2014 ... full service biopharmaceutical contract development and manufacturing organization ... by Progenics Pharmaceuticals, Inc., an oncology company focused ... and treating cancer, to manufacture the anti-prostate specific ... PSMA ADC product candidate. Under the agreement ...
(Date:8/20/2014)... analysis of patented university inventions licensed to biotechnology ... to commercialization. To open these roadblocks, the researchers ... during the discovery stage could lead to faster ... frequently derived from discoveries made in university laboratories ... known during clinical trials, which have a high ...
(Date:8/20/2014)... (PRWEB) August 20, 2014 High ... and apply the most complete climate and Earth ... demanding climate change issues. , Eight national laboratories, ... with the National Center for Atmospheric Research, four ... new effort. Other participating national laboratories include Argonne, ...
(Date:8/20/2014)... Not long ago, it was more ... performed late in the development cycle – even after ... trends suggest that, like many things GxP, expectations for ... years, multiple drug sponsors have been required by authorities ... during phase I/II. It’s not only clinical trial material ...
Breaking Biology Technology:Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 2Gallus Enters Agreement with Progenics Pharmaceuticals, Inc. for Manufacture of Anti-PSMA Monoclonal Antibody 3Early bottlenecks in developing biopharmaceutical products delay commercialization 2Early bottlenecks in developing biopharmaceutical products delay commercialization 3New Project Is the ACME of Addressing Climate Change 2New Project Is the ACME of Addressing Climate Change 3Are Extractable and Leachables going Phase-Appropriate? New Webinar Hosted by Xtalks 2
Cached News: